Articles & Video
Life Sciences in 2020: Predictions from industry insiders
Industry insiders predict how life sciences will change in 2020 in emerging therapies, clinical trials, regulations and agriculture.
REPORT: Cell and Gene Therapy Analytics, Manufacturing and Supply Chain
Explore and download our latest data report on Cell and Gene Therapy Analytics, Manufacturing and Supply Chain, in partnership with Intertek.
Insourcing vs outsourcing in cell and gene therapy manufacturing - WHITEPAPER
This whitepaper presents best practices for planning an outsourcing or insourcing strategy for manufacturing cell and gene therapies.
PharmAI – Industry is Smartening Up to Potential of Artificial Intelligence
Artificial Intelligence (AI) has enormous potential in changing the delivery of health care and improving patient outcomes, with applications in pattern detection, patient monitoring, disease diagnosis and treatment selection. The rationale is that AI can be used to enhance the decision-making process, taking into account far more data than are available to physicians via conventional means.
Evolving cost-effectiveness assessment as gene therapy care evolves
Gene therapies could revolutionize treatment of genetic disease, but should the cost-effectiveness of these drugs be measured?
What is cell therapy?
What is cell therapy? Discover how cell therapies work, what diseases can be treated, how much they cost and the companies behind them.
The challenge - and opportunity - of gene therapies in emerging markets
Bringing gene therapies to emerging markets: We look at the main obstacles to overcome and the huge opportunities.
Mesenchymal stem cells and understanding drug development processes
Sentien Biotech's VP of Operations, Chris Gemmiti, explores the current direction of mesenchymal stem cells and common hurdles in drug development.
What can reduce the cost of CAR-T therapy? - INDUSTRY VOICES
With such a high demand, what are the best available ways to lower the cost of CAR-T therapy? We ask three industry experts.
How Kite Pharma built a robust CAR-T supply chain
How did Kite Pharma build its robust supply chain for CAR-T therapies without a precedent? We found out from Director of Global Supply Chain David Kim and Sr. Manager of Packaging Engineering, Craig Vermeyen.
Defining standards for cell and gene therapy products
This on-demand webinar with Sheng Lin-Gibson at National Institute of Standards & Technology summarizes the latest developments in standardizing cell and gene therapy manufacturing and commercialization.
Cell and gene therapies: The latest developments in viral and non-viral vector manufacturing
Discover the latest developments in viral and non-viral vector manufacturing for cell and gene therapies.
Sourcing and qualification of raw materials for producing cell and gene therapies - WHITEPAPER
This whitepaper examines the key factors to consider in the sourcing and qualification of raw materials for cell and gene therapies.
INDUSTRY VOICES: Tackling the downstream supply chain challenges of cell and gene therapies
How can specific challenges affecting the downstream supply chain for cell and gene therapies be addressed? These industry experts gave us their view.
Validating effectiveness and payment for single treatment gene therapies
As regulatory approvals of gene therapies increase, how can we assess their market value and identify payment structures?
Viral safety in cell and gene therapies with Thomas R. Kreil, VP at Takeda
Thomas R. Kreil, Vice President of Global Pathogen Safety at Takeda, discusses the new challenges to viral safety that cell and gene therapies present and how new technologies are helping overcome them.
Cell and Gene Therapies: Viral and Non-Viral Vector Manufacturing - WHITEPAPER
Download this exclusive whitepaper on viral and non-viral vector manufacturing in cell and gene therapies.
The success of gene therapy depends on…diagnostic testing
It is little recognized that gene therapy success depends on the appropriate application of one or more specialized diagnostic tests.
Cell therapy process development: why and when?
Lior Raviv, VP Development at Pluristem, explains why early cell therapy process development and automation is essential to manufacturing.